Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


1,3-oxazoles (including hydrogenated)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514359000 - Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514376000 Chalcogen bonded directly to ring carbon of the oxazole ring 45
514375000 Polycyclo ring system having the oxazole ring as one of the cyclos 34
514377000 Nitrogen bonded directly to ring carbon of the oxazole ring 5
20110015241SUBSTITUTED HETEROCYCLES AND USE THEREOF - The invention relates to substituted heterocycles, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.01-20-2011
20090275627ALPHA2B AND ALPHA2C AGONISTS - Described herein are compounds that can be useful as bioactive agents. More specifically, the compounds described herein can be useful as both α11-05-2009
20100280085CHEMICAL COMPOUNDS - The use of a compound of formula (I) wherein X is (i), (ii) or (iii), where the substituents have the meanings assigned to them in claim 11-04-2010
20090209602CHEMICAL COMPOUNDS - Compounds of formula (I), or salts thereof, which inhibit acetyl CoA(acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided,08-20-2009
20100010060Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof - The invention relates to novel isoindolin-1-one, isoindolin-3-one and isoindoline-1,3-dione derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.01-14-2010
Entries
DocumentTitleDate
20090012136UNIT DOSE FORMULATIONS AND METHODS OF TREATING AND PREVENTING THROMBOSIS WITH THROMBOXANE RECEPTOR ANTAGONISTS - The present invention provides new methods of treating thrombosis and cardiovascular diseases using of antithrombotic agents, as well as methods of determining therapeutically effective amounts of antithrombotic agents and unit dose formulations thereof.01-08-2009
20100160397OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY - Compounds of formula (I), or salts thereof, which inhibit acetyl CoA (acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided,06-24-2010
20090281155Dimeric Small Molecule Potentiators of Apoptosis - Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of The compoundic mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.11-12-2009
20100105746METHOD FOR TREATING METABOLIC DISEASES - A method for treating a condition of low metabolic rate, dyslipidemia, excess adiposity and/or insulin resistance, or a disease or syndrome characterized by one or more of said conditions in a subject, comprises administering to the subject a therapeutically effective amount of romazarit or a pharmaceutically acceptable salt, ester or prodrug thereof.04-29-2010
20130072529PHARMACEUTICAL COMPOSITION COMPRISING ALEGLITAZAR - The invention relates to a pharmaceutical composition comprising aleglitazar and to the process of manufacture and uses thereof.03-21-2013
20080300287Peptidic Compounds - The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.12-04-2008
20090312378ECTOPARASITICIDE COMPOSITION AND A METHOD FOR EXTERMINATING ECTOPARASITES - The present invention provides an ectoparasiticide composition for animals having excellent photostability and a capability to suppress photodecomposition of the active ingredient, comprising etoxazole as an active ingredient, a UV absorber and a phenol antioxidant, and a method for exterminating ectoparasites using the composition.12-17-2009
20090318514Novel Pharmaceutical Compositions - The invention provides the use of compounds of formula (I) or pharmaceutically acceptable esters, amides, solvates or salts thereof, including salts of such esters or amides, and solvates of such esters, amides or salts, for the manufacture of a medicament for the treatment or prophylaxis of a condition that may be treated with a thyroid receptor agonist or partial agonist wherein R12-24-2009
20100113540Azole and Thiazole Derivatives and Their Use - Compounds of formula (I) are useful in the treatment of diseases where enhanced M3 receptor activation is implicated, such as respiratory tract diseases: wherein (i) R05-06-2010
20100120876COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE - The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.05-13-2010
20090264485Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents - Objects of the present invention are the compounds of formula I10-22-2009
20090030051Inhibitors of IMPDH enzyme - The present invention relates to compounds which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.01-29-2009
20120077858COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE - The present invention provides compounds, that are N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfonamido)propyl)benzyl)pyrrolidin-2-yl)oxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals. The compound may be represented by the following formula03-29-2012
20120077857INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS - The present invention provides a method for treating inflammation in a patient in need thereof comprising administering to said patient an effective amount of a compound according to formula03-29-2012
20110144168OXAZOLIDINE DERIVATIVES AS NMDA ANTAGONISTS - The present invention provides therapeutically active oxazolidine derivatives and compositions as NMDA antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological disorders, methods of providing neuroprotection under stress conditions such as a stroke, and methods of enhancing the brain's cognitive functions in mammals and humans. For example, the compounds can prevent glutamate-induced neuro-toxicity by inhibiting the activities of the NMDA receptor in the presence of toxic doses of NMDA. In addition, the compounds can potentiate the calcium current in the presence of low dose of NMDA.06-16-2011
20090264486Compounds, Compositions and Methods Comprising Isoxazole Derivatives - The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or encompassed by formulas I-II) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.10-22-2009
20090170915POLYMORPHIC FORMS OF (S)-1-cyanobutan-2-yl (S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)uriedo)phenyl)ethylcarbamate - The present invention relates to polymorphic forms of (S)-1-cyanobutan-2-yl (S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)phenyl)ethylcarbamate, pharmaceutical compositions thereof, processes to prepare therein, and uses therewith.07-02-2009
20100227901COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R09-09-2010
20100227902BIS-ARYL SULFONAMIDES - Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.09-09-2010
20090076102DEUTERIUM-ENRICHED MURAGLITAZAR - The present application describes deuterium-enriched muraglitazar, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20090069396Polyene Oxazoles and Processes for Their Preparation - This invention relates to novel biologically active polyene oxazoles, their pharmaceutically acceptable salts and derivatives, and to methods of obtaining them. One method for obtaining the compounds is by cultivation of 03-12-2009
20090143449Bi-Aryl or Aryl-Heteroaryl Substituted Indoles - The present invention relates to substituted indoles of Formula (I) useful as pharmaceutical compounds for treating respiratory disorders.06-04-2009
20090312379Dimeric Small Molecule Potentiators of Apoptosis - Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of The compoundic mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.12-17-2009
20120071526COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.03-22-2012
20110152330INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION - This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.06-23-2011
20110152331INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION - This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.06-23-2011
20100190835PHARMACEUTICAL COMPOSITION COMPRISING ALEGLITAZAR - The invention relates to a pharmaceutical composition comprising aleglitazar and to the process of manufacture and uses thereof.07-29-2010
20100093816 SALT - The invention provides [2-(4-chloro-benzyloxy)-ethyl]-[2-((R)-cyclohexyl-hydroxy-phenyl-methyl)-oxazol-5-yl-methyl]-dimethyl-ammonium napadisylate, pharmaceutical compositions containing it, and its use in therapy.04-15-2010
20080300286Tyrosine Derivatives Substituted By N-Arylacryloyl as Agonists of Hppar Alpha and/or Hppar Gamma - The present invention relates to a compound of formula I, racemates, optically active isomers, or pharmaceutically acceptable salts or solvates thereof, and a pharmaceutical composition comprising the compound, the various radicals in the formula I are the same as defined in the claims. The present invention also relates to a process for preparing the compound of formula I and use of said compound in the preparation of a medicament for the treatment of hyperglycemia, dyslipidemia, type II diabetes mellitus including associated diabetic dyslipidemia12-04-2008
20120270915FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN - Compounds of Formula 1 are described herein. These compounds may be administered to a patient for treatment of suffering from pain or other FAAH mediated conditions.10-25-2012
20120277275AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE - Compounds of formula (I) are useful in the treatment of diseases where enhanced M3 receptor activation is implicated, such as respiratory tract diseases:11-01-2012
20080275095Combination of Prostaglandin E2 Receptor Antagonists and Renin-Angiotensin System Inhibitors for Treating Renal Diseases - This invention relates to methods for treating renal diseases by using combination of prostaglandin E2 receptor antagonist and renin-angiotensin system inhibitor and pharmaceutical compositions for treating renal diseases comprising prostaglandin E2 receptor antagonist and renin-angiotensin system inhibitor.11-06-2008
20120329843FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN - The present invention provides a method of treating a patient suffering from pain or other FAAH mediated conditions by administering a fatty acid amide inhibiting amount of a compound represented by the formula:12-27-2012
20130096167METHODS FOR PRESERVING TECHNICAL PRODUCTS SUCH AS FUELS AND LUBRICANTS WITH A MICROBICIDAL COMPOSITION - Methods for preserving technical products such as fuels and lubricants with a microbicidal composition. The composition is made up of at least one formaldehyde donor compound and at least one antioxidant. The antioxidant is either a gallic ester, a phenol derivative, a L-ascorbic acid, including salts and derivatives thereof, a tocopherol or one of its associated derivatives.04-18-2013
20130150417COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE - The present invention provides compounds, that are N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfon-amido)propyl)benzyppyrrolidin-2-ypoxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals. The compound may be represented by the following formula wherein R06-13-2013
20130197044METHODS OF TREATING HEPATORENAL SYNDROME AND HEPATIC ENCEPHALOPATHY WITH THROMBOXANE-A2 RECEPTOR ANTAGONISTS - The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A08-01-2013

Patent applications in class 1,3-oxazoles (including hydrogenated)

Patent applications in all subclasses 1,3-oxazoles (including hydrogenated)